London( The COW News Digital) Scientists have reported a significant breakthrough in the treatment of resistant hypertension, unveiling a new drug that could provide relief for millions of patients worldwide who struggle to control high blood pressure.
Globally, an estimated 1.3 billion people suffer from hypertension, and a large portion of them fail to respond effectively to standard treatments. These patients face increased risks of heart attack, stroke, kidney failure, and premature death.
In a phase-three clinical trial, a new drug called baxdrostat demonstrated promising results. Conducted across 214 clinics worldwide, the study included nearly 800 patients with resistant hypertension. Participants were given a daily dose of either 1 mg or 2 mg of baxdrostat over a 12-week period.
Results revealed that patients experienced a significant drop in blood pressure, with reductions averaging 9–10 mmHg. Remarkably, the study also found that in about 40 percent of patients, blood pressure levels reached a healthy range after treatment.
Researchers say the findings are particularly encouraging for patients who have exhausted other treatment options without success. “Baxdrostat offers a new hope for those who continue to struggle with uncontrolled hypertension despite taking multiple medications,” said one of the study’s lead investigators.
The drug works by targeting the production of a hormone linked to blood pressure regulation, helping reduce cardiovascular stress. Unlike some traditional treatments, baxdrostat showed strong efficacy with minimal side effects reported during the trial.
Cardiologists have hailed the trial results as a potential game-changer. If approved for widespread use, baxdrostat could significantly reduce the global burden of hypertension-related complications, saving millions of lives and easing pressure on healthcare systems.
The trial outcomes also raise optimism about advancing personalized medicine, as researchers continue to identify patients who would benefit most from the new treatment. Regulatory approval processes are expected to begin soon, paving the way for broader availability in the coming years.
Experts caution, however, that longer-term studies will be needed to fully understand the drug’s safety profile and effectiveness in diverse populations. Nevertheless, the medical community sees baxdrostat as one of the most promising developments in cardiovascular medicine in recent years.
